SeekingAlpha · Feb 27, 2026
AN
NASDAQ · ANIP
ANI Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$71.46
Down-$0.27 (-0.37%)
Updated Sep 11, 2026, 1:48 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.66B
- P/E ratio
- 18.92
- Dividend yield
- 0.00%
- 52-week range
- $69.96 – $99.50
- Volume
- 228.89K
- Avg. volume
- 437.34K
Price performance
ANIP price history
1M range · 20 trading sessions · Daily adjusted prices
ANIP closed at $71.46 after 20 trading sessions, down 4.43% for the selected period.
- Last close
- $71.46
- Period change
- -4.43%
- Period low
- $70.23
- Period high
- $78.02
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $70.52 | $71.48 | $70.07 | $71.46 | 228.89K |
| Sep 9, 2026 | $70.23 | $70.925 | $69.96 | $70.70 | 298.34K |
| Sep 8, 2026 | $70.57 | $71.84 | $70.16 | $70.23 | 253.68K |
| Sep 4, 2026 | $71.35 | $72.055 | $71.115 | $71.23 | 219.22K |
| Sep 3, 2026 | $74.09 | $74.18 | $71.87 | $71.99 | 337.84K |
| Sep 2, 2026 | $72.53 | $73.435 | $72.41 | $73.06 | 287.61K |
| Sep 1, 2026 | $73.54 | $74.99 | $71.56 | $71.92 | 580.54K |
| Aug 31, 2026 | $72.81 | $73.53 | $71.77 | $73.25 | 340.55K |
| Aug 28, 2026 | $73.23 | $73.93 | $72.61 | $72.83 | 360.97K |
| Aug 27, 2026 | $73.735 | $74.50 | $73.24 | $73.51 | 316.61K |
| Aug 26, 2026 | $75.50 | $76.08 | $73.65 | $74.56 | 412.01K |
| Aug 25, 2026 | $74.24 | $75.84 | $73.56 | $75.65 | 811.89K |
| Aug 24, 2026 | $75.31 | $75.81 | $74.075 | $74.17 | 327.76K |
| Aug 21, 2026 | $77.33 | $77.81 | $74.81 | $75.35 | 379.16K |
| Aug 20, 2026 | $77.77 | $78.38 | $76.68 | $77.32 | 316.46K |
| Aug 19, 2026 | $77.79 | $78.9299 | $76.925 | $78.02 | 245.13K |
| Aug 18, 2026 | $76.77 | $77.385 | $76.43 | $76.87 | 286.47K |
| Aug 17, 2026 | $76.06 | $78.3399 | $75.755 | $76.00 | 260.82K |
| Aug 14, 2026 | $74.47 | $76.71 | $73.385 | $76.54 | 236.76K |
| Aug 13, 2026 | $75.48 | $75.745 | $74.00 | $74.77 | 330.21K |
Latest ANIP news
The latest Smart Investors Daily articles mentioning ANIP.
Stock researchCompany · Overview
ANIP research
Overview
Company profile and research snapshot.
Company profile
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $104.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Guggenheim | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Hold | — |
| Jul 17, 2026 | Canaccord Genuity | Hold | — |
| Jul 10, 2026 | Guggenheim | Buy | — |
| Jan 16, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Feb 27, 2026
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Surges 12% After Q4 Earnings Beat
ANI Pharmaceuticals' strong Q4 earnings beat estimates, driving shares up 12%. The company also reaffirmed its 2026 guidance above analyst expectations.
SeekingAlpha · Feb 27, 2026
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call February 27, 2026 8:00 AM ESTCompany ParticipantsNikhil Lalwani - President, CEO &...
Benzinga · Feb 27, 2026
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
ANI Pharma beats Q4 estimates, swings to profit, and sees over $1 billion in 2026 sales as Rare Disease revenue surges 50%.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
